Navigation Links
Dipexium Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
Date:8/12/2014

NEW YORK, Aug. 12, 2014 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today reported its financial results for the second quarter ended June 30, 2014 and provided an update on operational progress.

"The first half of 2014 has been an exciting period for Dipexium. We are very pleased with the progress achieved since the completion of our Initial Public Offering in March," stated David P. Luci, President & Chief Executive Officer of Dipexium. "Importantly, we remain on our stated timeline to complete enrollment in the OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials in the first quarter of 2015 and file a New Drug Application (NDA) for Locilex® in the second half of 2015."

Financial Results for the Second Quarter of 2014For the three months ended June 30, 2014, Dipexium reported a net loss of approximately $3.9 million, compared to $0.4 million for the three months ended June 30, 2013, an increase of $3.5 million, primarily due to a $2.5 million increase in research and development expenses and a $1.0 million increase in general and administrative expenses. The increased research and development expenses were primarily due to an increase of $1.9 million in research and development consulting-related expenses for the planning and execution of Locilex®'s Phase 1 and 3 clinical trials and a $0.6 million increase in research and development manufacturing costs related to manufacturing Locilex® for clinical trials. The increase in general and administrative expenses is primarily attributable to an increase of $0.7 million for compensation related expenses and an increase in $0.3 million in professional fees and office expenses.

For the six months end
'/>"/>

SOURCE Dipexium Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino
2. Rock Creek Pharmaceuticals Reports Second Quarter and Announces Clinical Update
3. AcelRx Pharmaceuticals Reports Second Quarter 2014 Financial Results
4. Inovio Pharmaceuticals Reports 2014 Second Quarter Financial Results
5. Absorption Pharmaceuticals CEO Jeff Abraham Discusses Promescent on KFI
6. Global Diabetic Neuropathy Market 2014-2018: Key Vendors are Eli Lilly and Co, Janssen Pharmaceuticals and Pfizer Inc.
7. Jazz Pharmaceuticals Announces Pricing of $500 Million of Exchangeable Senior Notes
8. AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
9. Global Transdermal Drug Delivery Market 2014-2018: Key Vendors are ANI Pharmaceuticals, Antares Pharma, Bayer, Janssen and Novartis
10. Access Pharmaceuticals Announces European License Agreement With Norgine
11. Vanda Pharmaceuticals Reports Second Quarter 2014 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 NeuroCall, Inc., ("NeuroCall") ... for its Telestroke and Teleneurology services. Dr. Ricardo ... commented, "We are extremely proud that our quality of ... we continue to provide lifesaving support and continuity of ... hospitals throughout the United States ." ...
(Date:10/1/2014)... 2014  Varian Medical Systems (NYSE: VAR ... the fourth quarter of fiscal year 2014 following the ... The news release will be followed by a teleconference ... The news release and a link to the conference ... at: www.varian.com/investor .  To access the teleconference call ...
(Date:10/1/2014)... 2014  Express Scripts (NASDAQ: ESRX ) ... Scripts Medicare ® Prescription Drug Plans (PDP) will ... WAG ) (NASDAQ: WAG ), ... support  for their Medicare dollars. Medicare beneficiaries ... or Choice plans for 2015 can ...
Breaking Medicine Technology:NeuroCall Awarded Joint Commission Accreditation 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4
... The U.S. Food and Drug Administration today announced ... Centers of Excellence in Regulatory Science and Innovation (CERSI). ... centers, which will be located at the University of ... and training needed to modernize and improve the ways ...
... Preserve Community Pharmacy Access NOW! (PCPAN) coalition ... Americans from increased costs and decreased access to quality ... Scripts Inc. and Medco Health Solutions Inc., two pharmacy ... on the coalition,s website, outlines the negative impact of ...
Cached Medicine Technology:FDA Invests $2 Million in Partnerships Through Centers of Excellence in Regulatory Science and Innovation 2Nationwide Coalition Issues 'Call To Action' To Stop Express Scripts/Medco Merger 2
(Date:10/1/2014)... 1, 2014 Patients with increased inflammation, including ... greatly increased risk of depression. For example, a ... hepatitis C virus infection causes depression in approximately ... more commonly known as fish oil, have a ... risk of heart disease and reducing triglyceride levels. ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 ... networking and relationship-marketing firm, announced today the ... Executive® and Project of the Year Awards ... makers representing organizations in financial services, commercial, ... large-scale technology endeavors that address key issues ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Between 23 ... in the U.S., according to figures from the National ... Diseases Association (AARDA), and many of them have something ... of having undiagnosed celiac disease. Gluten Free Therapeutics, ... awareness of undiagnosed celiac disease by publishing a series ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Scientists at ... three drugs that target immune system proteins has the ... has just posted details of the new study on ... now. , Researchers in the UWA School of ... anti-CTLA-4 drugs to mice with mesothelioma with promising results. ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
... journal Science that a team of Californian researchers have claimed ... plays an important role in making microscopic worms live longer//. ... equation, the longer you live, the greater your chances of ... is believed that a key element in determining whether a ...
... needs no treatment. Infants aging a few days may get baby ... ,It appears as red or white bumps/spots, from the stage ... infant. // Baby acne typically occurs on the face and chest. ... ointments or creams when it typically appears on face and chest ...
... in the June 2006 issue of the International Journal ... American Society //for Therapeutic Radiology and Oncology, says that ... partial radiation for the breast in order to combat ... ,A seroma is retention of fluid in ...
... up four super speciality hospitals in four zones of the ... covered under its scheme//. ,'These facilities will be ... Mumbai or Pune,' ESI director general Ramesh Inder Singh said ... be totally new ones or existing ESI hospitals would be ...
... latest cookbook by Britain-based celebrity chef Mridula Baljekar, has ... Asian Cuisine Cookbook' category//. ,Baljekar, who runs the ... the award at a star-studded ceremony in Kuala Lumpur, ... ,'I am absolutely overwhelmed and highly honoured ...
... and sexual dysfunction may find Viagra a good option ... express improved sexual enjoyment, orgasm and a less painful ... sexual dysfunction caused by vaginal dryness, and several other ... University of Catania in Italy, have said that the ...
Cached Medicine News:
Injection Cannula, Angled; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30); Angled at 45°, 2.5mm from Tip....
...
...
Lacrimal Cannula, Straight, Stepped DownSize: 19g x 1-1/2"....
Medicine Products: